An entropic safety catch controls Hepatitis C virus entry and antibody resistance

  1. Lenka Stejskal
  2. Mphatso D Kalemera
  3. Charlotte B Lewis
  4. Machaela Palor
  5. Lucas Walker
  6. Tina Daviter
  7. William D Lees
  8. David S Moss
  9. Myrto Kremyda-Vlachou
  10. Zisis Zisis Kozlakidis
  11. Giulia Gallo
  12. Dalan Bailey
  13. William Rosenberg
  14. Christopher JR Illingworth
  15. Adrian J Shepherd
  16. Joe Grove  Is a corresponding author
  1. University College London, United Kingdom
  2. University of Glasgow, United Kingdom
  3. Birkbeck, University of London, United Kingdom
  4. World Health Organization, France
  5. The Pirbright Institute, United Kingdom
  6. University of Cambridge, United Kingdom

Abstract

E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion remain unknown. Hypervariable region-1 (HVR-1) of E2 is a putative intrinsically disordered protein tail. Here, we demonstrate that HVR-1 has an autoinhibitory function that suppresses the activity of E1E2 on free virions; this is dependent on its conformational entropy. Thus, HVR-1 is akin to a safety catch that prevents premature triggering of E1E2 activity. Crucially, this mechanism is turned off by host receptor interactions at the cell surface to allow entry. Mutations that reduce conformational entropy in HVR-1, or genetic deletion of HVR-1, turn off the safety catch to generate hyper-reactive HCV that exhibits enhanced virus entry but is thermally unstable and acutely sensitive to neutralising antibodies. Therefore, the HVR-1 safety catch controls the efficiency of virus entry and maintains resistance to neutralising antibodies. This discovery provides an explanation for the ability of HCV to persist in the face of continual immune assault and represents a novel regulatory mechanism that is likely to be found in other viral fusion machinery.

Data availability

The underlying data for this manuscript are provided as a Source Data file. Full molecular dynamic simulation trajectories are available here: https://zenodo.org/record/4309544

Article and author information

Author details

  1. Lenka Stejskal

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Mphatso D Kalemera

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9461-1117
  3. Charlotte B Lewis

    University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Machaela Palor

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Lucas Walker

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Tina Daviter

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. William D Lees

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. David S Moss

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Myrto Kremyda-Vlachou

    Division of Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Zisis Zisis Kozlakidis

    International Agency for Research on Cancer, World Health Organization, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Giulia Gallo

    The Pirbright Institute, Pirbright, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Dalan Bailey

    Virus Programme, The Pirbright Institute, Guildford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5640-2266
  13. William Rosenberg

    Institute for Liver and Digestive Health, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-2304
  14. Christopher JR Illingworth

    Department of Genetics, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0030-2784
  15. Adrian J Shepherd

    Biological Sciences, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0194-8613
  16. Joe Grove

    University of Glasgow, Glasgow, United Kingdom
    For correspondence
    Joe.Grove@glasgow.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5390-7579

Funding

Wellcome Trust (107653/Z/15/Z)

  • Joe Grove

Medical Research Council (MC_UU_12014)

  • Joe Grove

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Fully consented blood samples (for IgG isolation) were collected from HCV+ patients under ethical approval: "Characterising and modifying immune responses in chronic viral hepatitis"; IRAS Number 43993; REC number 11/LO/0421.

Copyright

© 2022, Stejskal et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,159
    views
  • 247
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lenka Stejskal
  2. Mphatso D Kalemera
  3. Charlotte B Lewis
  4. Machaela Palor
  5. Lucas Walker
  6. Tina Daviter
  7. William D Lees
  8. David S Moss
  9. Myrto Kremyda-Vlachou
  10. Zisis Zisis Kozlakidis
  11. Giulia Gallo
  12. Dalan Bailey
  13. William Rosenberg
  14. Christopher JR Illingworth
  15. Adrian J Shepherd
  16. Joe Grove
(2022)
An entropic safety catch controls Hepatitis C virus entry and antibody resistance
eLife 11:e71854.
https://doi.org/10.7554/eLife.71854

Share this article

https://doi.org/10.7554/eLife.71854

Further reading

    1. Microbiology and Infectious Disease
    Xin Ma, Meng Li ... Xinyan Han
    Research Article

    As the largest mucosal surface, the gut has built a physical, chemical, microbial, and immune barrier to protect the body against pathogen invasion. The disturbance of gut microbiota aggravates pathogenic bacteria invasion and gut barrier injury. Fecal microbiota transplantation (FMT) is a promising treatment for microbiome-related disorders, where beneficial strain engraftment is a significant factor influencing FMT outcomes. The aim of this research was to explore the effect of FMT on antibiotic-induced microbiome-disordered (AIMD) models infected with enterotoxigenic Escherichia coli (ETEC). We used piglet, mouse, and intestinal organoid models to explore the protective effects and mechanisms of FMT on ETEC infection. The results showed that FMT regulated gut microbiota and enhanced the protection of AIMD piglets against ETEC K88 challenge, as demonstrated by reduced intestinal pathogen colonization and alleviated gut barrier injury. Akkermansia muciniphila (A. muciniphila) and Bacteroides fragilis (B. fragilis) were identified as two strains that may play key roles in FMT. We further investigated the alleviatory effects of these two strains on ETEC infection in the AIMD mice model, which revealed that A. muciniphila and B. fragilis relieved ETEC-induced intestinal inflammation by maintaining the proportion of Treg/Th17 cells and epithelial damage by moderately activating the Wnt/β-catenin signaling pathway, while the effect of A. muciniphila was better than B. fragilis. We, therefore, identified whether A. muciniphila protected against ETEC infection using basal-out and apical-out intestinal organoid models. A. muciniphila did protect the intestinal stem cells and stimulate the proliferation and differentiation of intestinal epithelium, and the protective effects of A. muciniphila were reversed by Wnt inhibitor. FMT alleviated ETEC-induced gut barrier injury and intestinal inflammation in the AIMD model. A. muciniphila was identified as a key strain in FMT to promote the proliferation and differentiation of intestinal stem cells by mediating the Wnt/β-catenin signaling pathway.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Gillian AM Tarr, Linda Chui ... Tim A McAllister
    Research Article

    Several areas of the world suffer a notably high incidence of Shiga toxin-producing Escherichia coli. To assess the impact of persistent cross-species transmission systems on the epidemiology of E. coli O157:H7 in Alberta, Canada, we sequenced and assembled E. coli O157:H7 isolates originating from collocated cattle and human populations, 2007–2015. We constructed a timed phylogeny using BEAST2 using a structured coalescent model. We then extended the tree with human isolates through 2019 to assess the long-term disease impact of locally persistent lineages. During 2007–2015, we estimated that 88.5% of human lineages arose from cattle lineages. We identified 11 persistent lineages local to Alberta, which were associated with 38.0% (95% CI 29.3%, 47.3%) of human isolates. During the later period, six locally persistent lineages continued to be associated with human illness, including 74.7% (95% CI 68.3%, 80.3%) of reported cases in 2018 and 2019. Our study identified multiple locally evolving lineages transmitted between cattle and humans persistently associated with E. coli O157:H7 illnesses for up to 13 y. Locally persistent lineages may be a principal cause of the high incidence of E. coli O157:H7 in locations such as Alberta and provide opportunities for focused control efforts.